| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 300110 from our risk checks.
Huaren Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.68 |
| 52 Week High | CN¥4.60 |
| 52 Week Low | CN¥2.77 |
| Beta | 0.38 |
| 11 Month Change | 0.82% |
| 3 Month Change | 13.58% |
| 1 Year Change | -15.21% |
| 33 Year Change | -10.24% |
| 5 Year Change | -3.66% |
| Change since IPO | -63.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300110 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.2% | -1.9% | -1.2% |
| 1Y | -15.2% | -5.0% | 3.1% |
Return vs Industry: 300110 underperformed the CN Pharmaceuticals industry which returned -5% over the past year.
Return vs Market: 300110 underperformed the CN Market which returned 3.1% over the past year.
Price Volatility
| 300110 volatility | |
|---|---|
| 300110 Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 300110 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300110's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,681 | Liang Hong | www.qdhuaren.com |
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, anti-tumor, and sugar metabolism; and medical instruments, such as disposable incision retractors, disposable cannula puncture devices disposable specimen extractors, abdominal suction tubes, incision retractor protectors, iodine protective caps, slip pads, respiratory oscillation expectoration machines, protective mask cup types, protective and foldable disposable masks, and medical protective masks.
Huaren Pharmaceutical Co., Ltd. Fundamentals Summary
| 300110 fundamental statistics | |
|---|---|
| Market cap | CN¥4.35b |
| Earnings (TTM) | CN¥146.51m |
| Revenue (TTM) | CN¥1.49b |
29.7x
P/E Ratio2.9x
P/S RatioIs 300110 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300110 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.49b |
| Cost of Revenue | CN¥943.59m |
| Gross Profit | CN¥550.37m |
| Other Expenses | CN¥403.85m |
| Earnings | CN¥146.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 36.84% |
| Net Profit Margin | 9.81% |
| Debt/Equity Ratio | 34.8% |
How did 300110 perform over the long term?
See historical performance and comparison